|
|
|
|
Managing Directors |
Mr. Eastman has over 30 years of experience in building healthcare
businesses. He began his career at American Cyanamid Company which was
acquired by American Home Products (now Wyeth). At Cyanamid, Mr. Eastman spent
15 years managing various pharmaceutical products, divisions and
subsidiaries in the U.S. and overseas. Since then he has helped build
three private healthcare companies. Under his leadership, Geron became
a cutting edge biotech company that grew from a venture-backed startup
to a publicly traded pioneer in the fields of regenerative medicine and
cancer. HCORP quickly established itself as the technology and market
leader in the emerging field of hospital-based, interactive patient
services and was sold to a diversified competitor. Most recently, at
Rinat
Neuroscience, a private biotech company spun out of Genentech
in late 2001, Mr. Eastman led the effort to recruit an experienced
management team and move Rinat’s first product for the treatment of pain into
clinical trials. Rinat was recently acquired by Pfizer in 2006.
Mr. Eastman has served on the Board of BIO, the biotechnology trade
organization, and currently serves as a trustee at The Buck Institute,
the largest non-profit research institute in the U.S. studying diseases
of aging. He serves as the Chairman of the Board at
Elusys Therapeutics
and on the Board of Directors for
Corium
International
and
OMT. Mr. Eastman earned his B.A. from
Williams College and his M.B.A. from Columbia University.
|
|
|
 |
|
|
|
